Bonum Therapeutics, Inc.

From the company

Bonum Therapeutics uses a novel, antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Its therapeutics remain inactive until bound to their target, a reversible regulation mechanism. The company is developing antibody-controlled cytokine-based therapeutics designed to enhance the anti-tumor immune response, with two programs in preclinical development. Its pipeline is focused on cancer, with interest in autoimmune disease, metabolic disorders, and pain management.